Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2018

  • ID: 4482752
  • Drug Pipelines
  • 465 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Bristol-Myers Squibb Co
  • F. Hoffmann-La Roche Ltd
  • Kamada Ltd
  • OncoImmune Inc
  • Targazyme Inc
  • MORE
Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2018, provides an overview of the Graft Versus Host Disease (GVHD) (Immunology) pipeline landscape.

Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, and diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment includes immunosuppressants.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graft Versus Host Disease (GVHD) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 8, 28, 9, 44, 9 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 3, 12 and 1 molecules, respectively.

Graft Versus Host Disease (GVHD) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD) (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Graft Versus Host Disease (GVHD) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Graft Versus Host Disease (GVHD) (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Graft Versus Host Disease (GVHD) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (GVHD) (Immunology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Graft Versus Host Disease (GVHD) (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Bristol-Myers Squibb Co
  • F. Hoffmann-La Roche Ltd
  • Kamada Ltd
  • OncoImmune Inc
  • Targazyme Inc
  • MORE
Introduction

Graft Versus Host Disease (GVHD) - Overview

Graft Versus Host Disease (GVHD) - Therapeutics Development

Graft Versus Host Disease (GVHD) - Therapeutics Assessment

Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development

Graft Versus Host Disease (GVHD) - Drug Profiles

Graft Versus Host Disease (GVHD) - Dormant Projects

Graft Versus Host Disease (GVHD) - Discontinued Products

Graft Versus Host Disease (GVHD) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Graft Versus Host Disease (GVHD), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by AbGenomics International Inc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Amgen Inc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Amunix Operating Inc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by AnaptysBio Inc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by apceth Biopharma GmbH, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Aptevo Therapeutics Inc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by arGEN-X BV, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Athersys Inc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals Inc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Biogen Inc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Bristol-Myers Squibb Co, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Capricor Therapeutics Inc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Cell2B Advanced Therapeutics SA, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Cellect Biotechnology Ltd, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by CSL Ltd, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Cynata Therapeutics Ltd, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Cytodyn Inc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Elsalys Biotech SAS, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Enlivex Therapeutics Ltd, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Escape Therapeutics Inc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Fate Therapeutics Inc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Generon (Shanghai) Corp Ltd, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Gilead Sciences Inc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by GlaxoSmithKline Plc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Incyte Corp, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Inspyr Therapeutics Inc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Jazz Pharmaceuticals Plc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Johnson & Johnson, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Kadmon Corp LLC, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Kamada Ltd, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Kiadis Pharma NV, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Kymab Ltd, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by LG Chem Ltd, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by MaaT Pharma, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by MacroGenics Inc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by MallInckrodt Plc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Mesoblast Ltd, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Millennium Pharmaceuticals Inc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Novartis AG, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by OncoImmune Inc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Pfizer Inc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Pharmicell Co Ltd, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Pluristem Therapeutics Inc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by REGiMMUNE Corp, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Sanofi, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Sarepta Therapeutics Inc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Seattle Genetics Inc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Seres Therapeutics Inc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Sigmoid Pharma Ltd, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Targazyme Inc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by TC BioPharm Ltd, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by TxCell SA, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by United BioPharma Inc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Vault Pharma Inc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by VBI Vaccines Inc, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Xenikos BV, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by XL-protein GmbH, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by Zai Lab Ltd, H1 2018

Graft Versus Host Disease (GVHD) - Pipeline by ZIOPHARM Oncology Inc, H1 2018

Graft Versus Host Disease (GVHD) - Dormant Projects, H1 2018

Graft Versus Host Disease (GVHD) - Dormant Projects, H1 2018 (Contd..1), H1 2018

Graft Versus Host Disease (GVHD) - Dormant Projects, H1 2018 (Contd..2), H1 2018

List of Figures

Number of Products under Development for Graft Versus Host Disease (GVHD), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • AbGenomics International Inc
  • Amgen Inc
  • Amunix Operating Inc
  • AnaptysBio Inc
  • apceth Biopharma GmbH
  • Aptevo Therapeutics Inc
  • arGEN-X BV
  • Athersys Inc
  • Bellicum Pharmaceuticals Inc
  • Biogen Inc
  • Bristol-Myers Squibb Co
  • Capricor Therapeutics Inc
  • Cell2B Advanced Therapeutics SA
  • Cellect Biotechnology Ltd
  • CSL Ltd
  • Cynata Therapeutics Ltd
  • Cytodyn Inc
  • Elsalys Biotech SAS
  • Enlivex Therapeutics Ltd
  • Escape Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics Inc
  • Generon (Shanghai) Corp Ltd
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Incyte Corp
  • Inspyr Therapeutics Inc
  • Jazz Pharmaceuticals Plc
  • Johnson & Johnson
  • Kadmon Corp LLC
  • Kamada Ltd
  • Kiadis Pharma NV
  • Kymab Ltd
  • LG Chem Ltd
  • MaaT Pharma
  • MacroGenics Inc
  • MallInckrodt Plc
  • Mesoblast Ltd
  • Millennium Pharmaceuticals Inc
  • Novartis AG
  • OncoImmune Inc
  • Pfizer Inc
  • Pharmicell Co Ltd
  • Pluristem Therapeutics Inc
  • REGiMMUNE Corp
  • Sanofi
  • Sarepta Therapeutics Inc
  • Seattle Genetics Inc
  • Seres Therapeutics Inc
  • Sigmoid Pharma Ltd
  • Takeda Pharmaceutical Co Ltd
  • Targazyme Inc
  • TC BioPharm Ltd
  • TxCell SA
  • United BioPharma Inc
  • Vault Pharma Inc
  • VBI Vaccines Inc
  • Xenikos BV
  • XL-protein GmbH
  • Zai Lab Ltd
  • ZIOPHARM Oncology Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll